Vice President, Program Team Lead

Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.

The Program Team Leader (PTL) for REM-422 is the single accountable leader for the strategic direction and operational execution of Remix’s most advanced program that integrates clinical, regulatory, CMC, medical affairs, and commercial functions into one aligned team to support the approval and commercialization of REM-422. 

The PTL is the connective tissue of the REM-422 program. The PTL serves as the point person for REM-422 at Remix’s Program meetings and Executive Leadership Team (ELT), owns the program budget, and represents the program. The ideal candidate combines deep development experience with strategic instincts and organizational leadership. Success in this role is measured by the ability to align diverse perspectives, resolve competing priorities, and move the team forward as one. 

• →Single point of accountability for driving the overall REM-422 Program strategy and accountable for execution excellence.
• →Integrate different functional perspectives including clinical, regulatory, CMC, translational, medical affairs, and commercial functions into a single, coherent strategy that maximizes the value REM-422.
• →Serve as the point person for REM-422 at the Executive Leadership Team (ELT) and Board of Directors; develop and present program updates and go/no-go recommendations with clarity and rigor.
• →Manage the critical path, scenario plans, and risk registry with a bias toward proactive resolution.
• →Drive lifecycle considerations into the development strategy.
• →Partner with Regulatory Affairs to develop and execute a global regulatory strategy, including FDA, EMA, and other priority health authority engagement; oversee key submissions (IND amendments, briefing documents, NDA/BLA/MAA).
• →Actively remove roadblocks and problem-solve to drive aggressive timelines by working hands-on with team members to anticipate issues and resolve cross-functional friction.
• →Cultivate strong team morale, a shared sense of mission, and a culture of living Remix's team behaviors; mentor and develop team members.
• →Build relationships with clinical thought leaders, patient advocacy communities, and key CRO and academic partners central to REM-422 execution. 

Remix's PTLs are expected to exemplify the following: 

• Strategic clarity. Owns trade-off decisions with confidence and communicates them with precision to Remix’s leadership.
• Integrative leadership. Brings cross-functional perspectives together and drives decision-making. Creates alignment without losing speed.
• Broad development fluency. Has seen programs across multiple phases and understands the commercial context well enough to develop in service of a winning label — not just an approval.
• Organizational savvy. Navigates governance, builds coalitions, and moves decisions through without losing momentum. Effective in both formal authority and informal influence.
• Drive and patient focus. Sets a pace. Removes roadblocks personally when needed. Keeps the patient in the room in every decision and uses unmet need as the ultimate arbiter of prioritization. 

• 15+ years of drug development experience with depth across clinical, regulatory and Tech Ops; experience in oncology strongly preferred.
• Demonstrated PTL or equivalent integrating leadership role on a late-stage asset through pivotal trials and global regulatory submission with direct accountability for cross-functional trade-off decisions.
• Hands-on resource allocation experience against development milestones. 

• Advanced degree (M.D., Ph.D., Pharm.D., or M.D./Ph.D.) in a relevant scientific or clinical discipline.
• Experience as a Global Franchise Lead or equivalent role with direct commercial exposure: launch planning, label strategy, or market access integration.
• Background in oncology drug development with experience in rare solid tumors (ACC, sarcoma, or similar) and/or hematologic malignancies (AML, MDS).  
• Prior experience at a clinical-stage biotech through commercial launch; comfort with ambiguity and rapid organizational change. 

$293,000 - $358,000 USD

This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable.  Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.